In short
This article discusses the ongoing clinical trials of Belapectin, also known as Galactoarabino-Rhamnogalacturonate, for the prevention of esophageal varices in patients with NASH cirrhosis. The study aims to evaluate the efficacy and safety of this innovative drug in addressing a significant complication of liver disease. We'll explore the trial's objectives, eligibility criteria, and potential impact on patient care.
At a glance
- Drug Name
- Belapectin (Galactoarabino-Rhamnogalacturonate)
- Study Type
- Phase 2b/3, Double-Blind, Randomized, Placebo-controlled
- Main Objective
- Evaluate efficacy in preventing esophageal varices in NASH cirrhosis
- Dosage
- 2 mg/kg and 4 mg/kg lean body mass
- Administration
- Intravenous injection
- Primary Endpoint
- Proportion of patients developing esophageal varices at 78 weeks
- Key Inclusion Criteria
- Age 18-75, NASH cirrhosis, evidence of portal hypertension
- Key Exclusion Criteria
- Existing esophageal varices, liver decompensation history
- Maximum Treatment Period
- 36 months
What is Belapectin?
Belapectin, also known as GR-MD-02, is an investigational medication being studied for its potential to prevent esophageal varices in patients with NASH cirrhosis. The active substance in Belapectin is called galactoarabino-rhamnogalacturonate, which is a type of polymer (a large molecule made up of repeating subunits).
Target Condition: Esophageal Varices in NASH Cirrhosis
NASH cirrhosis stands for Non-Alcoholic Steatohepatitis Cirrhosis. This is a severe form of liver disease that occurs when fat accumulates in the liver (fatty liver disease) and leads to inflammation, scarring, and eventually cirrhosis.
Esophageal varices are abnormally enlarged veins in the lower part of the esophagus (the tube connecting your throat to your stomach). They can develop in people with cirrhosis due to increased pressure in the portal vein, which carries blood from the intestines to the liver. These varices can potentially rupture and cause life-threatening bleeding.
Clinical Trial Details
A clinical trial is currently underway to evaluate the effectiveness and safety of Belapectin for preventing esophageal varices in patients with NASH cirrhosis. Here are some key details about the study:
- It's a Phase 2b/3 study, which means it's in an advanced stage of clinical research.
- The study is double-blind, randomized, and placebo-controlled, ensuring that neither the patients nor the researchers know who is receiving the actual drug or a placebo.
- It's being conducted at multiple centers internationally.
Eligibility Criteria
The study has specific criteria for who can participate. Some key inclusion criteria are:
- Age between 18 and 75 years old
- Evidence of portal hypertension (increased pressure in the portal vein)
- Confirmed diagnosis of NASH cirrhosis
- Absence of existing esophageal varices
Some exclusion criteria include:
- Presence of existing esophageal varices
- History of liver decompensation (when the liver can no longer perform its normal functions)
- Other causes of chronic liver disease besides NASH
- Certain medication usage or medical conditions that might interfere with the study
Potential Benefits
The main goal of this study is to see if Belapectin can prevent the development of esophageal varices in patients with NASH cirrhosis. If successful, this could potentially reduce the risk of life-threatening bleeding events in these patients.
The study is also looking at other potential benefits, including:
- Prevention of other complications of cirrhosis, such as ascites (fluid buildup in the abdomen) and hepatic encephalopathy (brain dysfunction due to liver disease)
- Potential impact on overall survival and need for liver transplantation
- Effects on liver function as measured by the MELD score (a scoring system used to assess the severity of chronic liver disease)
Administration and Dosage
Belapectin is administered as a solution for injection given intravenously (directly into a vein). The study is testing two different doses:
- 2 mg/kg of lean body mass
- 4 mg/kg of lean body mass
The maximum daily dose being tested is 4 mg/kg, and the treatment period may last up to 36 months (3 years).